Free tool
Cell therapy stocks
We cover 1 company grouped under the Cell therapy theme. The median market value in the group is $2.25B. Across the group, the median move over the past trading day is +3.60%. Price change over the past year runs from +1.0% to +1.0% across the middle 80 percent of the group, with a median of +1.0%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
1 company of 86 matches these filters.Clear filters
| Ticker | Company | Price | 1M return | YTD return | 1Y return |
|---|---|---|---|---|---|
| MSB.AX | Mesoblast Limited | 2.45 AUD | +19.85% | −11.73% | +1.03% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.